{"pmid":32326426,"title":"COVID-19: A Recommendation to Examine the Effect of Mouthrinses with beta-Cyclodextrin Combined with Citrox in Preventing Infection and Progression.","text":["COVID-19: A Recommendation to Examine the Effect of Mouthrinses with beta-Cyclodextrin Combined with Citrox in Preventing Infection and Progression.","Considered to be a major portal of entry for infectious agents, the oral cavity is directly associated with the evolutionary process of SARS-CoV-2 in its inhalation of ambient particles in the air and in expectorations. Some new generations of mouth rinses currently on the market have ingredients that could contribute to lower the SARS-CoV-2 viral load, and thus facilitate the fight against oral transmission. If chlorhexidine, a usual component of mouth rinse, is not efficient to kill SARS-CoV-2, the use of a mouth rinses and/or with local nasal applications that contain beta-cyclodextrins combined with flavonoids agents, such as Citrox, could provide valuable adjunctive treatment to reduce the viral load of saliva and nasopharyngeal microbiota, including potential SARS-CoV-2 carriage. We urge national agencies and authorities to start clinical trials to evaluate the preventive effects of betaCD-Citrox therapeutic oral biofilm rinses in reducing the viral load of the infection and possibly disease progression.","J Clin Med","Carrouel, Florence","Conte, Maria Pia","Fisher, Julian","Goncalves, Lucio Souza","Dussart, Claude","Llodra, Juan Carlos","Bourgeois, Denis","32326426"],"abstract":["Considered to be a major portal of entry for infectious agents, the oral cavity is directly associated with the evolutionary process of SARS-CoV-2 in its inhalation of ambient particles in the air and in expectorations. Some new generations of mouth rinses currently on the market have ingredients that could contribute to lower the SARS-CoV-2 viral load, and thus facilitate the fight against oral transmission. If chlorhexidine, a usual component of mouth rinse, is not efficient to kill SARS-CoV-2, the use of a mouth rinses and/or with local nasal applications that contain beta-cyclodextrins combined with flavonoids agents, such as Citrox, could provide valuable adjunctive treatment to reduce the viral load of saliva and nasopharyngeal microbiota, including potential SARS-CoV-2 carriage. We urge national agencies and authorities to start clinical trials to evaluate the preventive effects of betaCD-Citrox therapeutic oral biofilm rinses in reducing the viral load of the infection and possibly disease progression."],"journal":"J Clin Med","authors":["Carrouel, Florence","Conte, Maria Pia","Fisher, Julian","Goncalves, Lucio Souza","Dussart, Claude","Llodra, Juan Carlos","Bourgeois, Denis"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32326426","week":"202017|Apr 20 - Apr 26","doi":"10.3390/jcm9041126","keywords":["2019-ncov","covid-19","citrox","sars-cov-2","microbiome","mouthrinse","oral cavity","viral load","beta-cyclodextrins"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["beta-Cyclodextrins","betadex","Flavonoids","Chlorhexidine"],"_version_":1664996914857246720,"score":8.518259,"similar":[{"pmid":32217947,"title":"Perioperative COVID-19 Defense: An Evidence-Based Approach for Optimization of Infection Control and Operating Room Management.","text":["Perioperative COVID-19 Defense: An Evidence-Based Approach for Optimization of Infection Control and Operating Room Management.","We describe an evidence-based approach for optimization of infection control and operating room management during the COVID-19 pandemic. Confirmed modes of viral transmission are primarily but not exclusively contact with contaminated environmental surfaces and aerosolization. Evidence-based improvement strategies for attenuation of residual environmental contamination involve a combination of deep cleaning with surface disinfectants and ultraviolet light (UV-C). (1) Place alcohol-based hand rubs on the IV pole to the left of the provider. Double glove during induction. (2) Place a wire basket lined with a zip closure plastic bag, on the IV pole to the right of the provider. Place all contaminated instruments in the bag (i.e. laryngoscope blades and handles) and close. Designate and maintain clean and dirty areas. After induction of anesthesia, wipe down all equipment and surfaces with disinfection wipes that contain a quaternary ammonium compound and alcohol. Use a top down cleaning sequence adequate to reduce bioburden. Treat operating rooms using UV-C. (3) Decolonize patients using pre-procedural chlorhexidine wipes, 2 doses of nasal povidone iodine within one hour of incision, and chlorhexidine mouth rinse. (4) Create a closed lumen IV system and use hub disinfection. (5) Provide data feedback by surveillance of ESKAPE transmission. (6) To reduce the use of surgical masks and to reduce potential COVID-19 exposure, use relatively long (e.g., 12-hour) staff shifts. If there are 8 essential cases to be done (each lasting 1-2 hours), the ideal solution is to have 2 teams complete the 8 cases, not 8 first case starts. (7) Do 1 case in each operating room daily, with terminal cleaning after each case including UV-C or equivalent. (8) Do not have patients go into a large, pooled phase I post-anesthesia care unit, because of the risk of contaminating facility at large along with many staff. Instead, have most patients recover in the room where they had surgery, like done routinely in Japan. These 8 programmatic recommendations stand on a substantial body of empirical evidence characterizing the epidemiology of perioperative transmission and infection development made possible by support from the Anesthesia Patient Safety Foundation (APSF).","Anesth Analg","Dexter, Franklin","Parra, Michelle C","Brown, Jeremiah R","Loftus, Randy W","32217947"],"abstract":["We describe an evidence-based approach for optimization of infection control and operating room management during the COVID-19 pandemic. Confirmed modes of viral transmission are primarily but not exclusively contact with contaminated environmental surfaces and aerosolization. Evidence-based improvement strategies for attenuation of residual environmental contamination involve a combination of deep cleaning with surface disinfectants and ultraviolet light (UV-C). (1) Place alcohol-based hand rubs on the IV pole to the left of the provider. Double glove during induction. (2) Place a wire basket lined with a zip closure plastic bag, on the IV pole to the right of the provider. Place all contaminated instruments in the bag (i.e. laryngoscope blades and handles) and close. Designate and maintain clean and dirty areas. After induction of anesthesia, wipe down all equipment and surfaces with disinfection wipes that contain a quaternary ammonium compound and alcohol. Use a top down cleaning sequence adequate to reduce bioburden. Treat operating rooms using UV-C. (3) Decolonize patients using pre-procedural chlorhexidine wipes, 2 doses of nasal povidone iodine within one hour of incision, and chlorhexidine mouth rinse. (4) Create a closed lumen IV system and use hub disinfection. (5) Provide data feedback by surveillance of ESKAPE transmission. (6) To reduce the use of surgical masks and to reduce potential COVID-19 exposure, use relatively long (e.g., 12-hour) staff shifts. If there are 8 essential cases to be done (each lasting 1-2 hours), the ideal solution is to have 2 teams complete the 8 cases, not 8 first case starts. (7) Do 1 case in each operating room daily, with terminal cleaning after each case including UV-C or equivalent. (8) Do not have patients go into a large, pooled phase I post-anesthesia care unit, because of the risk of contaminating facility at large along with many staff. Instead, have most patients recover in the room where they had surgery, like done routinely in Japan. These 8 programmatic recommendations stand on a substantial body of empirical evidence characterizing the epidemiology of perioperative transmission and infection development made possible by support from the Anesthesia Patient Safety Foundation (APSF)."],"journal":"Anesth Analg","authors":["Dexter, Franklin","Parra, Michelle C","Brown, Jeremiah R","Loftus, Randy W"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32217947","week":"202013|Mar 23 - Mar 29","doi":"10.1213/ANE.0000000000004829","source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Japan"],"countries":["Japan"],"countries_codes":["JPN|Japan"],"e_drugs":["Chlorhexidine","Quaternary Ammonium Compounds","Alcohols","Povidone-Iodine"],"_version_":1664638743044161536,"score":354.8266},{"pmid":32220180,"title":"[Oral Health Management of Children during the Epidemic Period of Coronavirus Disease 2019].","text":["[Oral Health Management of Children during the Epidemic Period of Coronavirus Disease 2019].","Coronavirus disease 2019 (COVID-19) is becoming a major public health event affecting China and even the whole world. During the epidemic period of corona virus disease, appropriate oral health management and disease prevention of children is very important for children's oral and general health. In order to prevent the occurrence of cross-infection and epidemic spreading of COVID-19 during dental practice, the recommendations to parents include: not only training children to maintain hand hygiene at home, exercise appropriately, strengthen physical resistance, but also helping children develop good oral and diet habit such as effective brushing and flossing to avoid oral diseases and emergency. If non-emergency oral situation occur, parents could assist their child to take home based care such as rinsing to relieve the symptoms. When oral emergencies such as acute pulpitis, periapical periodontitis, dental trauma, oral and maxillofacial infections happen, parents and children should visit dental clinic in time with correct personal protection. During the epidemic period, children's oral emergencies should be treated in accordance with current guidelines and control of COVID-19.","Sichuan Da Xue Xue Bao Yi Xue Ban","Wang, Yan","Zhou, Chen-Chen","Shu, Rui","Zou, Jing","32220180"],"abstract":["Coronavirus disease 2019 (COVID-19) is becoming a major public health event affecting China and even the whole world. During the epidemic period of corona virus disease, appropriate oral health management and disease prevention of children is very important for children's oral and general health. In order to prevent the occurrence of cross-infection and epidemic spreading of COVID-19 during dental practice, the recommendations to parents include: not only training children to maintain hand hygiene at home, exercise appropriately, strengthen physical resistance, but also helping children develop good oral and diet habit such as effective brushing and flossing to avoid oral diseases and emergency. If non-emergency oral situation occur, parents could assist their child to take home based care such as rinsing to relieve the symptoms. When oral emergencies such as acute pulpitis, periapical periodontitis, dental trauma, oral and maxillofacial infections happen, parents and children should visit dental clinic in time with correct personal protection. During the epidemic period, children's oral emergencies should be treated in accordance with current guidelines and control of COVID-19."],"journal":"Sichuan Da Xue Xue Bao Yi Xue Ban","authors":["Wang, Yan","Zhou, Chen-Chen","Shu, Rui","Zou, Jing"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32220180","week":"202013|Mar 23 - Mar 29","doi":"10.12182/20200360101","keywords":["children","coronavirus disease 2019","oral emergency","oral health management"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664638742973906944,"score":299.23538},{"pmid":32205204,"pmcid":"PMC7102549","title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.","text":["Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.","BACKGROUND: Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the role of hydroxychloroquine on respiratory viral loads. PATIENTS AND METHODS: French Confirmed COVID-19 patients were included in a single arm protocol from early March to March 16(th), to receive 600mg of hydroxychloroquine daily and their viral load in nasopharyngeal swabs was tested daily in a hospital setting. Depending on their clinical presentation, azithromycin was added to the treatment. Untreated patients from another center and cases refusing the protocol were included as negative controls. Presence and absence of virus at Day6-post inclusion was considered the end point. RESULTS: Six patients were asymptomatic, 22 had upper respiratory tract infection symptoms and eight had lower respiratory tract infection symptoms. Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported of untreated patients in the literature. Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination. CONCLUSION: Despite its small sample size our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.","Int J Antimicrob Agents","Gautret, Philippe","Lagier, Jean-Christophe","Parola, Philippe","Hoang, Van Thuan","Meddeb, Line","Mailhe, Morgane","Doudier, Barbara","Courjon, Johan","Giordanengo, Valerie","Vieira, Vera Esteves","Dupont, Herve Tissot","Honore, Stephane","Colson, Philippe","Chabriere, Eric","La Scola, Bernard","Rolain, Jean-Marc","Brouqui, Philippe","Raoult, Didier","32205204"],"abstract":["BACKGROUND: Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the role of hydroxychloroquine on respiratory viral loads. PATIENTS AND METHODS: French Confirmed COVID-19 patients were included in a single arm protocol from early March to March 16(th), to receive 600mg of hydroxychloroquine daily and their viral load in nasopharyngeal swabs was tested daily in a hospital setting. Depending on their clinical presentation, azithromycin was added to the treatment. Untreated patients from another center and cases refusing the protocol were included as negative controls. Presence and absence of virus at Day6-post inclusion was considered the end point. RESULTS: Six patients were asymptomatic, 22 had upper respiratory tract infection symptoms and eight had lower respiratory tract infection symptoms. Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported of untreated patients in the literature. Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination. CONCLUSION: Despite its small sample size our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin."],"journal":"Int J Antimicrob Agents","authors":["Gautret, Philippe","Lagier, Jean-Christophe","Parola, Philippe","Hoang, Van Thuan","Meddeb, Line","Mailhe, Morgane","Doudier, Barbara","Courjon, Johan","Giordanengo, Valerie","Vieira, Vera Esteves","Dupont, Herve Tissot","Honore, Stephane","Colson, Philippe","Chabriere, Eric","La Scola, Bernard","Rolain, Jean-Marc","Brouqui, Philippe","Raoult, Didier"],"date":"2020-03-25T11:00:00Z","year":2020,"_id":"32205204","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.ijantimicag.2020.105949","keywords":["2019-nCoV","COVID-19","SARS-CoV-2","azithomycin","clinical trial","hydroxychloroquine"],"source":"PubMed","locations":["French"],"countries":["France"],"countries_codes":["FRA|France"],"topics":["Treatment"],"weight":1,"e_drugs":["Chloroquine","Hydroxychloroquine","Azithromycin"],"_version_":1663352133735415808,"score":259.86975},{"pmid":32297925,"title":"Sequential analysis of viral load in a neonate and her mother infected with SARS-CoV-2.","text":["Sequential analysis of viral load in a neonate and her mother infected with SARS-CoV-2.","We report changes in viral load over time in a 27-day old neonate with COVID-19 who presented with fever, cough, and vomiting. SARS-CoV-2 RNA was detected in the nasopharynx, oropharynx, stool, saliva, plasma, and urine. The highest viral RNA copies in nasopharynx decreased over time while viral load in stool remained high.","Clin Infect Dis","Han, Mi Seon","Seong, Moon-Woo","Heo, Eun Young","Park, Ji Hong","Kim, Namhee","Shin, Sue","Cho, Sung Im","Park, Sung Sup","Choi, Eun Hwa","32297925"],"abstract":["We report changes in viral load over time in a 27-day old neonate with COVID-19 who presented with fever, cough, and vomiting. SARS-CoV-2 RNA was detected in the nasopharynx, oropharynx, stool, saliva, plasma, and urine. The highest viral RNA copies in nasopharynx decreased over time while viral load in stool remained high."],"journal":"Clin Infect Dis","authors":["Han, Mi Seon","Seong, Moon-Woo","Heo, Eun Young","Park, Ji Hong","Kim, Namhee","Shin, Sue","Cho, Sung Im","Park, Sung Sup","Choi, Eun Hwa"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32297925","week":"202016|Apr 13 - Apr 19","doi":"10.1093/cid/ciaa447","keywords":["covid-19","sars-cov-2","coronavirus","neonate","viral load"],"source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1664641388327731200,"score":244.74121},{"pmid":32221523,"title":"Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients.","text":["Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients.","BACKGROUND: Coronavirus disease 2019 (COVID-19) has become a public health emergency. The widely used reverse transcription PCR (RT-PCR) method has limitations for clinical diagnosis and treatment. METHODS: A total of 323 samples from 76 COVID-19 confirmed patients were analyzed by droplet digital PCR (ddPCR) and RT-PCR based two target genes (ORF1ab and N). Nasal swabs, throat swabs, sputum, blood, and urine were collected. Clinical and imaging data were obtained for clinical staging. RESULTS: In 95 samples tested positive by both methods, the cycle threshold (Ct) of RT-PCR was highly correlated with the copy numbed of ddPCR (ORF1ab gene, R2 = 0.83; N gene, R2 = 0.87). 4 (4/161) negative and 41 (41/67) single-gene positive samples tested by RT-PCR were positive according to ddPCR with viral load ranging from 11.1 to 123.2 copies/test. Then the viral load of respiratory samples was compared and the average viral load in sputum (17429 +/- 6920 copies/test) was found to be significantly higher than in throat swabs (2552 +/- 1965 copies/test, p < 0.001) and nasal swabs (651 +/- 501 copies/test, p < 0.001). Furthermore, the viral load in the early and progressive stages were significantly higher than that in the recovery stage (46800 +/- 17272 vs 1252 +/- 1027, p < 0.001) analyzed by sputum samples. CONCLUSIONS: Quantitative monitoring of viral load in lower respiratory tract samples helps to evaluate disease progression, especially in cases of low viral load.","Clin Infect Dis","Yu, Fengting","Yan, Liting","Wang, Nan","Yang, Siyuan","Wang, Linghang","Tang, Yunxia","Gao, Guiju","Wang, Sa","Ma, Chengjie","Xie, Ruming","Wang, Fang","Tan, Chianru","Zhu, Lingxiang","Guo, Yong","Zhang, Fujie","32221523"],"abstract":["BACKGROUND: Coronavirus disease 2019 (COVID-19) has become a public health emergency. The widely used reverse transcription PCR (RT-PCR) method has limitations for clinical diagnosis and treatment. METHODS: A total of 323 samples from 76 COVID-19 confirmed patients were analyzed by droplet digital PCR (ddPCR) and RT-PCR based two target genes (ORF1ab and N). Nasal swabs, throat swabs, sputum, blood, and urine were collected. Clinical and imaging data were obtained for clinical staging. RESULTS: In 95 samples tested positive by both methods, the cycle threshold (Ct) of RT-PCR was highly correlated with the copy numbed of ddPCR (ORF1ab gene, R2 = 0.83; N gene, R2 = 0.87). 4 (4/161) negative and 41 (41/67) single-gene positive samples tested by RT-PCR were positive according to ddPCR with viral load ranging from 11.1 to 123.2 copies/test. Then the viral load of respiratory samples was compared and the average viral load in sputum (17429 +/- 6920 copies/test) was found to be significantly higher than in throat swabs (2552 +/- 1965 copies/test, p < 0.001) and nasal swabs (651 +/- 501 copies/test, p < 0.001). Furthermore, the viral load in the early and progressive stages were significantly higher than that in the recovery stage (46800 +/- 17272 vs 1252 +/- 1027, p < 0.001) analyzed by sputum samples. CONCLUSIONS: Quantitative monitoring of viral load in lower respiratory tract samples helps to evaluate disease progression, especially in cases of low viral load."],"journal":"Clin Infect Dis","authors":["Yu, Fengting","Yan, Liting","Wang, Nan","Yang, Siyuan","Wang, Linghang","Tang, Yunxia","Gao, Guiju","Wang, Sa","Ma, Chengjie","Xie, Ruming","Wang, Fang","Tan, Chianru","Zhu, Lingxiang","Guo, Yong","Zhang, Fujie"],"date":"2020-03-30T11:00:00Z","year":2020,"_id":"32221523","week":"202014|Mar 30 - Apr 05","doi":"10.1093/cid/ciaa345","keywords":["covid-19","rt-pcr","sars-cov-2","viral load","ddpcr"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664638629687853056,"score":242.06111}]}